


ONLINE DATA SUPPLEMENT

Supplementary Figure 1. Baseline height SDS versus (A) baseline age and (B) duration of pcJIA (n = 186). One patient underwent no baseline assessment at or before screening and is not included. pcJIA: polyarticular-course juvenile idiopathic arthritis; SDS: standard deviation score.



Supplementary Table 1. Placebo treatment in part 2 (n = 81).

Time of Escape or Transition to TCZ Treatment ^a	Placebo Infusions Received, n	Weeks on Placebo, n	Patients, n ^b
Escaped by week 20	1	4	16
Escaped by week 24	2	8	6
Escaped by week 28	3	12	6
Escaped by week 32	4	16	5
Escaped by week 36	5	20	5
Completed week 40	6	24	43

^aPatients could receive a maximum of 6 placebo infusions (maximum, 24 weeks) after week 16 if they did not escape to TCZ treatment before week 40.

^bOverall, 38 of 81 (46.9%) patients escaped to TCZ and 43 of 81 (53.1%) completed weeks 16-40 on placebo. Three of the 84 patients randomly assigned to placebo in part 2 discontinued before receiving a single dose.

TCZ: tocilizumab.

Supplementary Table 2. Summary of growth data.

Height SDS, mean ± SD	Growth Analysis Subset ^a n = 187	Patients at Tanner Stage ≤3 at Baseline n = 123
Baseline	-0.5 ± 1.2	-0.6 ± 1.1
Week 52	-0.5 ± 1.1	-0.4 ± 1.2
Week 104	-0.2 ± 1.1	-0.2 ± 1.1

^aPatients who received ≥1 dose of TCZ and did not receive growth hormone.

SD: standard deviation; SDS: standard deviation score.

Supplementary Figure 2. Baseline height SDS versus height SDS at year 2 in the growth population (n = 187). Eighty-four patients were randomly assigned to receive placebo treatment during the part 2 withdrawal phase; approximately 50% of those patients escaped to TCZ before week 40. Black diagonal line represents no change in height SDS. Black circles represent patients randomly assigned to placebo in part 2. Red unfilled circles represent patients who received TCZ continuously. SDS: standard deviation score.

